Objectives To investigate the real-world incidence of serious infections (SI), herpes zoster (HZ) and hepatitis B virus (HBV) ...

Objective Strategies to Embrace Living with Lupus Fearlessly (SELF) is an online self-management education programme for ...

We read with great interest the recent article by Tsai et al,1 which compared characteristics between primary neuromyelitis ...

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...

Objectives Systemic lupus erythematosus (SLE) is characterized by unpredictable flares that lead to significant morbidity. Early identification of impending flares could improve patient outcomes. This ...

Objectives Lupus nephritis (LN) is a highly heterogenous disease with variable risks of end-stage kidney disease (ESKD) across histological classes and ethnic groups. Current remission criteria based ...

Objective Lupus nephritis (LN) is a major complication and cause of death among patients with SLE. This research used in vivo and in vitro experiments to explore the therapeutic potential of metformin ...

Objectives To explore the effects of anti-ribosomal P protein (anti-P) and anti-N-methyl-D-aspartic acid receptor subunit 2 (anti-NR2) autoantibodies on depression and cognitive dysfunction and their ...

Objective Lupus nephritis (LN) is diagnosed by biopsy, but longitudinal monitoring assessment methods are needed. Here, in this preliminary and hypothesis-generating study, we evaluate the potential ...

Conclusions Novel antibodies aPS/PT IgG are inversely associated with C3 and C4 levels in APS, independently from treatment, Lupus Anticoagulant or triple positivity. aPS/PT IgG are positively ...

Objective Fatigue has been reported as the most disturbing symptom in a majority of patients with SLE. Depression is common and often severe. Together these symptoms cause significant morbidity and ...

Objectives Following the successful AURORA-1 and AURORA-2 trials, voclosporin was incorporated into the KDIGO 2024 clinical guidelines for the management of active Class III or IV lupus nephritis, ...